IPA Defends COVID-19 Vaccine Safety Amid Karnataka Allegations

India Pharma Outlook Team | Thursday, 03 July 2025

 IPA Defends COVID-19 Vaccine Safety Amid Karnataka Allegations, India Pharma Outlook

In a recent response to the reports in Karnataka's Hassan district claiming COVID-19 vaccines led to heart attack deaths, the Indian Pharmaceutical Alliance (IPA) expressed its strong defense of both vaccine safety and the integrity of regulatory approval for vaccines.

The IPA stated they are confident that all vaccines used in India are rigorously tested, scientifically evaluated, and approved through the same regulatory procedures as normal medicines.

IPA Secretary-General Sudarshan Jain stated he found the claims baseless, and warned that dissemination of misinformation could hinder public health initiatives and public trust and confidence in science and innovation. Jain stated India produces about 60% of the world's vaccine needs, and all approved vaccines went through rigorous documentation and clinical evaluations.

Without naming Karnataka Chief Minister Siddaramaiah, who linked COVID-19 vaccines with a spate of heart attack deaths in the state's Hassan district, Indian Pharmaceutical Alliance (IPA) said, "Misinformation and distortion of facts endanger public health and undermine the trust built on science and patient care globally".

Also Read: Anti-Infectives: How New Research is Shaping Infection Control

The IPA further stated that vaccines were thoroughly reviewed and that no shortcuts were taken, then they were approved with the approval of expert panels. As India is the world's vaccine supply ecosystem, the IPA encouraged everyone to base their decisions on science and data, and not speculation to maintain public confidence in immunization programs.

© 2025 India Pharma Outlook. All Rights Reserved.